Stay updated on PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed study criteria and the addition of new identifiers and collaborators related to a clinical study on metastatic solid tumors. The principal investigator's name has also been removed.SummaryDifference26%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 13, 2025.SummaryDifference0.4%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.